|Articles|April 1, 2004

Solution could control inflammation in less time

Irvine, CA-ISTA Pharmaceuticals Inc. plans to file a new drug application with the FDA during the second quarter of 2004 for its 0.1% bromfenac sodium ophthalmic solution (Xibrom). The topical, twice-daily, non-steroidal, anti-inflammatory solution is being developed for the treatment of ocular inflammation after cataract surgery.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME